Joel Isaacson & Co. LLC Has $2.27 Million Stock Holdings in Merck & Co., Inc. $MRK

Joel Isaacson & Co. LLC decreased its stake in Merck & Co., Inc. (NYSE:MRK) by 2.7% in the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 28,664 shares of the company’s stock after selling 784 shares during the period. Joel Isaacson & Co. LLC’s holdings in Merck & Co., Inc. were worth $2,269,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also modified their holdings of the company. Barnes Dennig Private Wealth Management LLC bought a new position in Merck & Co., Inc. in the first quarter valued at approximately $27,000. Legend Financial Advisors Inc. acquired a new stake in shares of Merck & Co., Inc. in the 2nd quarter valued at approximately $25,000. CBIZ Investment Advisory Services LLC grew its stake in shares of Merck & Co., Inc. by 141.7% in the first quarter. CBIZ Investment Advisory Services LLC now owns 377 shares of the company’s stock valued at $34,000 after buying an additional 221 shares in the last quarter. MorganRosel Wealth Management LLC acquired a new position in Merck & Co., Inc. during the first quarter worth $36,000. Finally, Fiduciary Wealth Partners LLC acquired a new position in Merck & Co., Inc. during the first quarter worth $48,000. Institutional investors and hedge funds own 76.07% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of research analysts have recently commented on MRK shares. Wells Fargo & Company decreased their price objective on shares of Merck & Co., Inc. from $97.00 to $90.00 and set an “equal weight” rating for the company in a research report on Wednesday, July 30th. Morgan Stanley decreased their price objective on shares of Merck & Co., Inc. from $99.00 to $98.00 and set an “equal weight” rating on the stock in a report on Thursday, July 10th. Weiss Ratings restated a “hold (c-)” rating on shares of Merck & Co., Inc. in a research note on Saturday, September 27th. Finally, Berenberg Bank lowered shares of Merck & Co., Inc. from a “buy” rating to a “hold” rating and decreased their price target for the company from $100.00 to $90.00 in a research note on Wednesday, September 17th. One investment analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating, fourteen have assigned a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat, Merck & Co., Inc. has a consensus rating of “Hold” and an average target price of $104.31.

Merck & Co., Inc. Stock Down 0.4%

NYSE MRK opened at $88.83 on Tuesday. The company has a current ratio of 1.42, a quick ratio of 1.17 and a debt-to-equity ratio of 0.69. Merck & Co., Inc. has a 1-year low of $73.31 and a 1-year high of $111.58. The company has a 50 day moving average of $82.96 and a 200-day moving average of $81.48. The company has a market cap of $221.88 billion, a price-to-earnings ratio of 13.69, a PEG ratio of 0.92 and a beta of 0.37.

Merck & Co., Inc. (NYSE:MRK) last issued its quarterly earnings results on Tuesday, July 29th. The company reported $2.13 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.03 by $0.10. Merck & Co., Inc. had a return on equity of 41.05% and a net margin of 25.79%.The business had revenue of $15.81 billion for the quarter, compared to the consensus estimate of $15.92 billion. Merck & Co., Inc. has set its FY 2025 guidance at 8.870-8.970 EPS. On average, equities research analysts expect that Merck & Co., Inc. will post 9.01 earnings per share for the current fiscal year.

Merck & Co., Inc. Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Tuesday, October 7th. Investors of record on Monday, September 15th will be given a $0.81 dividend. The ex-dividend date is Monday, September 15th. This represents a $3.24 dividend on an annualized basis and a dividend yield of 3.6%. Merck & Co., Inc.’s dividend payout ratio (DPR) is presently 49.92%.

Merck & Co., Inc. Company Profile

Merck & Co, Inc is a health care company, which engages in the provision of health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products. It operates through the following segments: Pharmaceutical, Animal Health, and Other. The Pharmaceutical segment includes human health pharmaceutical and vaccine products.